[go: up one dir, main page]

MX2022002527A - Metodos de preparacion de linfocitos t para la terapia con linfocitos t. - Google Patents

Metodos de preparacion de linfocitos t para la terapia con linfocitos t.

Info

Publication number
MX2022002527A
MX2022002527A MX2022002527A MX2022002527A MX2022002527A MX 2022002527 A MX2022002527 A MX 2022002527A MX 2022002527 A MX2022002527 A MX 2022002527A MX 2022002527 A MX2022002527 A MX 2022002527A MX 2022002527 A MX2022002527 A MX 2022002527A
Authority
MX
Mexico
Prior art keywords
lymphocytes
preparing
methods
lymphocyte therapy
population
Prior art date
Application number
MX2022002527A
Other languages
English (en)
Inventor
Thomas Charles Pertel
Yajin Ni
Mark W Leonard
Chupei Zhang
Original Assignee
Allogene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allogene Therapeutics Inc filed Critical Allogene Therapeutics Inc
Publication of MX2022002527A publication Critical patent/MX2022002527A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente descripción, se proporcionan métodos para preparar linfocitos T para la terapia con linfocitos T que comprenden poner en contacto una población de células a una densidad celular predeterminada, con una concentración de una nanomatriz anti-CD3/CD28 y cultivar las células que de esta manera producen una población de linfocitos T que comprende un mayor porcentaje de al menos un subtipo de linfocitos T. En algunas modalidades, el método aumenta el porcentaje de linfocitos T de memoria madre.
MX2022002527A 2019-09-03 2020-09-02 Metodos de preparacion de linfocitos t para la terapia con linfocitos t. MX2022002527A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962895381P 2019-09-03 2019-09-03
PCT/US2020/049074 WO2021046134A1 (en) 2019-09-03 2020-09-02 Methods of preparing t cells for t cell therapy

Publications (1)

Publication Number Publication Date
MX2022002527A true MX2022002527A (es) 2022-04-01

Family

ID=72521739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002527A MX2022002527A (es) 2019-09-03 2020-09-02 Metodos de preparacion de linfocitos t para la terapia con linfocitos t.

Country Status (11)

Country Link
US (1) US20210062150A1 (es)
EP (1) EP4025688A1 (es)
JP (1) JP7785662B2 (es)
KR (1) KR20220054383A (es)
CN (1) CN114341348A (es)
AU (1) AU2020343300B2 (es)
BR (1) BR112022003852A2 (es)
CA (1) CA3147441A1 (es)
IL (1) IL291074A (es)
MX (1) MX2022002527A (es)
WO (1) WO2021046134A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297751A (en) 2020-04-28 2022-12-01 Lyell Immunopharma Inc Methods for culturing cells
CN113046306B (zh) * 2021-03-12 2022-10-18 广东东阳光药业有限公司 一种多能干细胞的培养方法
WO2022215718A1 (ja) * 2021-04-08 2022-10-13 武田薬品工業株式会社 Ｔ細胞活性化方法
EP4363558A1 (en) * 2021-07-01 2024-05-08 Kite Pharma, Inc. Closed-system and method for autologous and allogeneic cell therapy manufacturing
CA3252265A1 (en) * 2022-05-30 2023-12-07 Mediterranea Theranostic S.R.L. Anti-idiotype antibodies and their uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA3179835A1 (en) 2011-01-18 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
BR112014006176A8 (pt) 2011-09-16 2017-09-12 Univ Pennsylvania Rna transcrito in vitro ou rna sintético, composição, método para gerar uma população de células t geneticamente modificadas por rna, e, uso de uma célula t geneticamente modificada
EP2711418B1 (en) * 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
CA2946222C (en) * 2014-04-24 2020-12-22 Miltenyi Biotec Gmbh Method for automated generation of genetically modified t cells

Also Published As

Publication number Publication date
IL291074A (en) 2022-05-01
AU2020343300A1 (en) 2022-03-03
AU2020343300B2 (en) 2026-01-22
KR20220054383A (ko) 2022-05-02
WO2021046134A9 (en) 2021-10-07
JP7785662B2 (ja) 2025-12-15
EP4025688A1 (en) 2022-07-13
BR112022003852A2 (pt) 2022-05-31
US20210062150A1 (en) 2021-03-04
WO2021046134A1 (en) 2021-03-11
CA3147441A1 (en) 2021-03-11
CN114341348A (zh) 2022-04-12
JP2022546537A (ja) 2022-11-04

Similar Documents

Publication Publication Date Title
MX2022002527A (es) Metodos de preparacion de linfocitos t para la terapia con linfocitos t.
MX2021012461A (es) Procesos para preparar y usar un secretoma derivado de células madre mesenquimales.
EA201992795A1 (ru) Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе
AR102888A1 (es) Animales no humanos que tienen un gen humanizado de agrupamiento de diferenciación 47
CO2022009119A2 (es) Métodos para mejorar el cultivo celular con proteínas específicas de cada especie o específicas de cada género y las aplicaciones de los mismos
CO2022011682A2 (es) Método para producir linfocitos citolíticos naturales a partir de células madre pluripotentes
AU2018285579A1 (en) Blood vessel organoid, methods of producing and using said organoids
MX2021010556A (es) Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente.
CY1121243T1 (el) Χρηση μιας λαμινινης για τη διαφοροποιηση πλειοδυναμων κυτταρων σε κυτταρικες σειρες ηπατοκυτταρων
GB2555728A (en) Cancer cell enrichment system
MX2019010575A (es) Metodo para producir anticuerpos multiespecificos.
EA201792661A1 (ru) Способ получения антител против т-клеточного рецептора
MY174899A (en) Method and apparatus for examining eggs
EP3879607C0 (en) CATHODE ACTIVE MATERIAL, METHOD FOR MANUFACTURING IT AND LITHIUM BATTERY CONTAINING IT
MX2024001443A (es) Sistemas inducibles para alterar la expresión génica en células hipoinmunógenas.
CO2021005061A2 (es) Método para la activación y proliferación de las células t
BR112021024946A2 (pt) Célula de mamífero, método para produzir uma célula de mamífero implantável, e, uso de uma célula de mamífero
SG11202104775SA (en) Animal Cell Growth Promoter, Medium For Culturing Animal Cells, And Device For Culturing Animal Cells
AR072909A1 (es) Metodo de ajuste para lentes multifocales
MX2024000972A (es) Metodos y sistemas para el mantenimiento y crecimiento escalable de celulas madre mediante el uso de optogenetica en suspension.
AR116481A1 (es) Biomaterial que comprende células madre derivadas de tejido adiposo y gelatina y método para producir el mismo
MX2021013005A (es) Metodos de fabricacion de celulas car-t alogenicas.
EP4456238A4 (en) SOLID ELECTROLYTE, ITS MANUFACTURING PROCESS AND SECONDARY LITHIUM BATTERY INCLUDING IT
PE20220003A1 (es) Metodo para la prediccion de eficacia del tratamiento de hemoglobinopatia
CO2023018654A2 (es) Método para producir linfocitos citolíticos naturales a partir de células madre pluripotentes